Absci Corp. (ABSI)
NASDAQ:ABSI
Want to see ABSI full AI Analyst Report?
ABSI Stock Chart & Stats
$3.58
$0.12(3.91%)
At close: 4:00 PM EST
$3.58
$0.12(3.91%)
Day’s Range― - ―
52-Week Range$2.24 - $7.34
Previous CloseN/A
Volume51.94M
Average Volume (3M)5.25M
Market Cap
$990.00M
Enterprise Value$1.05B
Total Cash (Recent Filing)$125.70M
Total Debt (Recent Filing)$4.42M
Price to Earnings (P/E)―
Beta2.42
Next Earnings
Aug 18, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding155,905,060
10 Day Avg. Volume4,394,155
30 Day Avg. Volume5,249,601
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)2.52
Price to Sales (P/S)170.48
P/FCF Ratio-5.08
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue570.89
Enterprise Value/Gross Profit-43.35
Enterprise Value/Ebitda-9.07
Forecast
1Y Price Target
$8.59Price Target Upside139.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.75
Revenue Forecast (FY)$7.64M
Bulls Say, Bears Say
Bulls Say
AI-driven Discovery PlatformAbSci’s Origin-1/generative and agentic AI capabilities and high-throughput wet lab create a durable competitive advantage: they can shorten discovery cycles, improve hit quality, and scale services for partners, supporting repeat collaborations and lower unit costs over time.
Balance Sheet Strength & RunwayRelatively strong liquidity and very low leverage (debt-to-equity ~0.03) materially reduce near-term solvency risk. This gives management time to execute clinical readouts and seek partnerships or non-dilutive deals without immediate forced financing, supporting multi-quarter strategic execution.
Large TAM & Defined Clinical RoadmapA clearly articulated development timeline combined with very large addressable markets (AGA and endometriosis) creates durable optionality: positive POC or favorable regulatory positioning could unlock high-value partnerships, downstream economics, and expanded platform adoption by partners.
Bears Say
High Cash Burn & LossesSustained negative operating and free cash flow means ongoing financing or milestone revenue is needed to fund operations. Persistent cash burn limits optionality, increases dilution risk or dependence on partners, and constrains ability to scale commercial or discovery activities absent material revenue gains.
Minimal Recurring RevenueExtremely small service/milestone revenue creates lumpy, unpredictable top-line dynamics. Reliance on partnerships or milestone payments reduces revenue visibility, complicates reinvestment planning, and raises execution sensitivity to clinical timing and partner negotiations over multiple quarters.
Concentrated Program & Clinical RiskNarrowing focus toward ABS-201/ABS-202 increases binary outcome exposure: trial delays, negative POC, or high placebo response could materially impair pipeline value. Deprioritizing oncology reduces program diversification, raising financing and partnership pressure if lead-data don't de-risk the story.
AbSci News
ABSI FAQ
What was Absci Corp.’s price range in the past 12 months?
Absci Corp. lowest stock price was $2.24 and its highest was $7.34 in the past 12 months.
What is Absci Corp.’s market cap?
Absci Corp.’s market cap is $990.00M.
When is Absci Corp.’s upcoming earnings report date?
Absci Corp.’s upcoming earnings report date is Aug 18, 2026 which is in 76 days.
How were Absci Corp.’s earnings last quarter?
Absci Corp. released its earnings results on May 07, 2026. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.2 by $0.01.
Is Absci Corp. overvalued?
According to Wall Street analysts Absci Corp.’s price is currently Undervalued.
Does Absci Corp. pay dividends?
Absci Corp. does not currently pay dividends.
What is Absci Corp.’s EPS estimate?
Absci Corp.’s EPS estimate is -0.2.
How many shares outstanding does Absci Corp. have?
Absci Corp. has 155,905,060 shares outstanding.
What happened to Absci Corp.’s price movement after its last earnings report?
Absci Corp. reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.2. Following the earnings report the stock price went up 2.609%.
Which hedge fund is a major shareholder of Absci Corp.?
Currently, no hedge funds are holding shares in ABSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbSci Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.59 (139.82% Upside)
$8.59 (139.82% Upside)
Blogger Sentiment
Neutral
ABSI Sentiment 50%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $429.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.2%
Last 30 Days ▲ 7.5%
Last 30 Days ▲ 7.5%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
132.60%
12-Months-Change
Fundamentals
Return on Equity
-63.58%
Trailing 12-Months
Asset Growth
-15.85%
Trailing 12-Months
Company Description
Absci Corp.
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
ABSI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed clear progress on the lead program (ABS-201) with favorable early safety/PK signals, supportive PK modeling for an infrequent dosing profile, a defined clinical timeline (interim 13-week readout in H2 2026 and full 26-week POC in early 2027), and a substantial addressable market supported by consumer and KOL research. The company expanded its prolactin-focused pipeline (ABS-202), sharpened strategic focus by de‑emphasizing oncology, and reported a cash runway into H1 2028. Offsetting these positives are a very small quarter revenue base ($200k), a cash decline of ~12.9% QoQ to $125.7M, increased R&D spend (+17.7% YoY), and remaining clinical and regulatory risks (directional 13-week readout, placebo risk in endometriosis). Overall, the call emphasized promising clinical and commercial potential but also highlighted near-term execution and financing sensitivities.View all ABSI earnings summariesABSI Stock 12 Month Forecast
Average Price Target
$8.59
▲(139.82% Upside)
Technical Analysis
Autolus Therapeutics
―
―
ADC Therapeutics
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Ownership Overview
6.65% Insiders
19.39% Mutual Funds
30.17% Other Institutional Investors
23.54% Public Companies and
Individual Investors